Review ArticleClinical Review

2025 update of the Greig Health Record

Part 1—what’s new?

Anita Greig, Fereshte Lalani, Cara Dosman, Akshay Verma, Jordana Sheps and Naima Javaid
Canadian Family Physician January 2026; 72 (1) 31-38; DOI: https://doi.org/10.46747/cfp.720131

Abstract

Objective To review a selection of new resources and updated recommendations from the third update of the Greig Health Record (GHR).

Sources of information Pediatric preventive care literature was reviewed using PubMed and Google Scholar databases. Systematic reviews of subtopics were evaluated where available. Guidance and supporting evidence were reviewed from the Canadian Paediatric Society, the American Academy of Pediatrics, the Canadian Task Force on Preventive Health Care, the United States Preventive Services Task Force, the National Advisory Committee on Immunization, and the Centers for Disease Control and Prevention.

Main message In this 2025 update the following topics have been added or revised: confidentiality, capacity, and consent in pediatric patients; developmental assessment; poverty screening; sexual health and consent; menstrual health history; contraception; guidance for detection and prevention of sexually transmitted infections; radon as an environmental hazard; updated ferritin standards; vaccine hesitancy; and updated dosing for human papillomavirus vaccination.

Conclusion The third update of the GHR provides recent evidence-based recommendations and detailed guidance for clinicians providing pediatric preventive care.

The Greig Health Record (GHR) is an evidence-based care guide used in preventive care visits for children and adolescents aged 6 to 17 years old. It is available from https://greighealthrecord.ca, along with a comprehensive technical report that reviews the supporting evidence. This article provides an overview of a selection of the new resources and updated recommendations from the third update of the GHR.1-3 This 2025 update also includes French translations of preventive care checklists and resources.

Sources of information

Searches for pediatric preventive care literature for the period of 2016 to 2025 were performed using PubMed and Google Scholar databases. Systematic reviews of subtopics were evaluated where available. Additionally, guidance and supporting evidence were reviewed from major Canadian and American agencies, including the Canadian Paediatric Society (CPS), the American Academy of Pediatrics, the Canadian Task Force on Preventive Health Care, the United States Preventive Services Task Force, the National Advisory Committee on Immunization (NACI), and the Centers for Disease Control and Prevention.

Main message

Confidentiality, capacity, and consent in pediatric patients. Confidentiality is central to a successful therapeutic relationship, particularly with adolescent patients.4-6 Each physician is responsible for assessing their patient’s capacity to consent to the proposed medical intervention (including obtaining a history and performing physical examination). In the child and adolescent population, capacity may vary depending on the nature of the intervention and should be evaluated on a case-by-case basis.7-9 The GHR now provides guidance in the form of definitions and resources (Box 1).6,8,10,11

Box 1.

Confidentiality, capacity, and consent

This chart is not a comprehensive guide. See individual references for details and clarification.

Confidentiality

  • The patient’s right to privacy in their medical care and health records is protected by federal legislation and no age is specified

Capacity

  • Depends on ability to understand the medical problem; the proposed treatment; the alternatives (if any) to the proposed treatment; and the option of refusing treatment or of it being withheld or withdrawn

  • Depends on the ability to appreciate the reasonably foreseeable consequences of accepting and refusing the proposed treatment

  • Depends on the ability to make a decision that is not substantially based on delusions or depression

Consent

  • Requirements include the following: the patient or decision maker must be capable (capacity); all relevant information must be given to make an informed decision; and it must be voluntary and without coercion

  • No Canadian standard for age of consent. Legislation varies between provinces and territories

Data from Agostino et al,6 Canadian Medical Protective Association,8 Etchells et al,10 and Coughlin.11

Developmental assessment. A new Canadian resource table is available for school-aged children. Generally, surveillance consists of questions about school performance and enjoyment as well as peer relationships. A table of developmental attainments for those aged 6 to 12 years is provided when a more in-depth assessment is needed (Table 1).12

View this table:
Table 1.

Crucial skills in school-aged child development: At every age ask about academics. Is there a concern about the child’s writing, reading, or math?

Poverty screening. Approximately 1 in 5 children in Canada lives in poverty.13 Children growing up in low-income families have poorer physical and mental health outcomes.14-19 Identifying children at risk and providing families with resources may improve long-term health. A validated screening tool to administer to parents and caregivers, as well as a link to the Centre for Effective Practice’s poverty tool, are included in the GHR.20,21 The tool assists clinicians in guiding families to available resources (Box 2).20,21

Box 2.

Poverty screening tool: Ask “Do you ever have difficulty making ends meet by the end of the month?”

Data from Centre for Effective Practice20 and Persaud et al.21

Sexual health and consent. Sexual health history in pediatric populations should explore whether sex is consensual and free from exploitation and abuse, and confirm that the patient is capable of giving consent.22-24 For the protection of young persons, Canadian laws provide detail regarding ability to consent to sexual activity by age and presence or absence of exploitation (Table 2).23,25

View this table:
Table 2.

Consent for sexual activity: All sexual activity without consent is a criminal offence, regardless of age. Sexual activity ranges from kissing and fondling to intercourse.

Menstrual health history. Adolescent females are often reluctant to raise menstrual concerns with health care providers.26,27 Dysmenorrhea is the most common gynecologic concern and a leading cause of absenteeism from school and work in this age group.28,29 A table regarding normal menarche, cycle regularity, and flow, as well as signs and symptoms requiring further inquiry, is now included in the GHR (Box 3).30-33

Box 3.

Menstrual health topics to ask about

  • Age of menarche—average is 12 to 13 years

  • Cycles and regularity—may take 2 to 3 years to establish regular cycles after menarche, initial cycles are 20 to 45 days vs 24 to 38 for adults

  • Length of periods—average duration is 5 days, >7 days is prolonged

  • Heavy bleeding or clotting—average volume is 40 mL, heavy >80 mL. A saturated pad or tampon absorbs 5 to 15 mL

  • Clots larger than a quarter are excessive. A menstrual chart is available from https://www.betteryouknow.org/sites/default/files/2022-08/BetterYouKnow-Menstrual-Chart-Scoring-System.pdf

  • Symptoms related to cycle include mood, irregular bleeding, fatigue, and shortness of breath

  • Consider screening for anemia or iron deficiency for heavy, prolonged, or frequent bleeding or for those with symptoms of fatigue or shortness of breath

  • Dysmenorrhea

  • Amenorrhea: primary, no period by age 16; secondary, no period for 6 months

Data from Peacock et al,30 Centers for Disease Control and Prevention,31 United States Preventive Services Task Force,32 and Graham et al.33

Contraception for adolescents. The GHR updates contraception recommendations from the CPS and the Society of Obstetricians and Gynaecologists of Canada. These include specific guidance for adolescents regarding bone mineral density, thromboembolic events, extended-use oral contraceptives, quick-start regimens, and year-long prescriptions. Long-acting reversible contraceptives are the preferred option. When choosing combined oral contraceptive pills, those with ethinyl estradiol below 30 μg per day should be avoided due to possible impact on bone mineralization in adolescents (Box 4).34-36 Emergency contraception should be discussed where applicable. In Canada, emergency oral contraception is available in most regions without a prescription.38 Options including oral contraceptives, intrauterine devices, and intrauterine systems are outlined (Box 5).37-40

Box 4.

Contraception recommendations: Recommendations for contraception do not address sexually transmitted infection prevention.

Recommend contraceptives in order of effectiveness:

  1. LARCs: IUD, IUS, or implantable etonogestrel device

  2. Hormonal plus time of intercourse method

  3. Hormonal: OCPs, transdermal patch, vaginal ring, injectable

  4. Used at time of intercourse: male and female condoms, diaphragms, cervical caps, sponges, and spermicide

History and physical examination

  • Take a complete medical history

  • Ask about migraines with aura, which is an absolute contraindication to estrogen use. Progesterone-only methods may be used

  • Examination—weight and blood pressure

  • Provide contraception without a pelvic examination unless required (eg, for IUD insertion)

Prescribing

  • Quick-start approach—do not wait for next menses if reasonable certainty they are not pregnant; use a back-up method for 7 days after starting an OCP or implantable etonogestrel device outside of days 1 to 5 of the menstrual cycle

  • Provide 1-year prescriptions to increase adherence (ie, for non-LARC)

  • Choose OCP with 30 or 35 μg of ethinyl estradiol—lower levels may have negative effects on bone mineral density for adolescents

  • For OCPs extended cycles and continuous use of active pills are effective

Precautions and contraindications

  • For individuals >90 kg—certain contraceptives may have reduced effectiveness

  • Combined OCP contraindications: containing estrogen, migraine with aura, history of venous thromboembolism or pulmonary embolus, systemic lupus erythematosus with antiphospholipid antibodies, factor V Leiden deficiency, estrogen-sensitive tumours

  • Use SOGC guidelines to inform contraceptive choice

Discuss emergency contraception and condom use as appropriate

IUD—intrauterine device, IUS—intrauterine system, LARC—long-acting reversible contraception, OCP—oral contraceptive pill, SOGC—Society of Obstetricians and Gynaecologists of Canada.

Data from Di Meglio et al34 and Black et al.35,36

Box 5.

Emergency contraception options

  1. Emergency over-the-counter hormonal pills (easiest to obtain, but reduced efficacy for patients weighing >75 kg)

    • Oral levonorgestrel

    • Ulipristal acetate

    • Combined OCP (lower efficacy than above)

  2. Copper IUD (most effective)

  3. Levonorgestrel IUS

When prescribing,

  • Ask about timing of unprotected intercourse (determine if within window of effectiveness)

  • Assess risk of pre-existing pregnancy

  • Ask if unprotected intercourse was coerced

  • Assess for STI risk and need for postexposure prophylaxis; offer testing for STIs

  • Consider a pregnancy test 3 weeks post use

IUD—intrauterine device, IUS—intrauterine system, OCP—oral contraceptive pill, STI—sexually transmitted infection.

Data from the Society of Obstetricians and Gynaecologists of Canada,37 Bancsi and Grindrod,39 and the Society of Obstetricians and Gynaecologists of Canada.40

Newer guidance for detection and prevention of sexually transmitted infections. Vaginal self-swabs for the detection of chlamydia and gonorrhea are recommended owing to evidence that detection of chlamydia may be improved and the ease and privacy of collecting a vaginal self-swab makes this a preferred option.40,41 Sampling from other sites, such as from rectal and oropharyngeal areas, is recommended based on practices and sexual history, with self-swabs as an option with equal sensitivity.42-44 Pre-exposure vaccination is recommended for persons at risk for Mpox due to practices and local epidemiology.45,46 Guidance is provided for pre-exposure prophylaxis for individuals at higher risk for human immunodeficiency virus exposure, including those who report condomless anal sex and higher-risk situations. Counselling patients who are at risk should include discussion of pre- and postexposure prophylaxis (Boxes 6 and 7).47-55

Box 6.

PrEP for HIV

PrEP indications

  • MSM and transgender women, who may report condomless anal sex and other risk factors54

  • Heterosexual partner reporting condomless vaginal or anal sex with a partner with a substantial or non-negligible risk of transmissible HIV

  • People who inject drugs and share injection paraphernalia with a person with a non-negligible risk of HIV infection

Medication: 300 mg of tenofovir disoproxil fumarate with 200 mg of emtricitabine in a single tablet (TDF-FTC)

Regimen

  • Recommended: 1 tablet of TDF-FTC daily48

  • Alternative on demand: 2 tablets of TDF/FTC 2 to 24 hours prior to first sexual exposure, followed by 1 pill daily until 48 hours after last sexual activity53

Postexposure prophylaxis requires additional medications and dosing

HIV—human immunodeficiency virus, MSM—men who have sex with men, PrEP—pre-exposure prophylaxis.

Box 7.

PEP for HIV

PEP indications

  • Needs to be started within 72 h (the sooner the better)

  • Recommended for HIV-negative individuals after moderate- to high-risk exposure of HIV transmission with a person who has a substantial risk of having transmissible HIV

  • Can be considered for HIV-negative individuals after an exposure that is moderate or high risk for HIV transmission with a person who has a low but non-negligible risk of having transmissible HIV

HIV—human immunodeficiency virus, PEP—postexposure prophylaxis.

Data from Tan et al54 and Billick et al.55

Radon as an environmental hazard. A new national study about radon estimates that 17.8% of Canadian homes have high levels of radon. Previous estimates were lower, at 7%. Radon gas is found naturally in soil and rock and can seep in through building foundations. Long-term radon exposure, especially in children, increases the risk of lung cancer.56,57 The GHR has added radon to its list of environmental hazards with links to a Canadian guide for radon reduction (Box 8).58

Box 8.

Radon exposure and radon reduction

Parachute Canada—poisoning: https://parachute.ca/en/injury-topic/poisoning/

Health Canada—radon reduction: https://www.canada.ca/en/health-canada/services/health-risks-safety/radiation/radon/resources.html

Updated ferritin standards. Ferritin level standards in children are different from adults. New guidelines state that, for pediatric populations, the following values warrant treatment: less than 20 μg/L or between 20 and 30 μg/L if accompanied by anemia, microcytosis, or other risk factors.59

Vaccine hesitancy. Counselling vaccine-hesitant patients and parents presents a challenge to providers. Guidance suggests strategies that can be used to deliver evidence-based information in a way that promotes understanding.60,61 Counselling resources are provided (Box 9).60

Box 9.

Counselling vaccine-hesitant parents

Start early, even antenatally

Present vaccination as the default approach

Build trust

  • Spend time

  • Be respectful, validate concerns

  • Be knowledgeable

  • Be honest about side effects

  • Provide reassurance on a robust vaccine safety system

Focus on protection of the child and the community

Tell stories (of own children, vaccine successes, non-vaccination consequences)

Address pain and fear

Vaccination handouts and fact sheets: https://www.ontario.ca/document/immunization-well-child-toolkit

Data from Shen et al.60

Updated dosing for human papillomavirus vaccination. The NACI strongly recommends all individuals aged 9 to 26 years be vaccinated. Individuals aged 9 to 20 years now require only 1 dose and those aged 22 to 26 years require 2 doses.62,63

Conclusion

This update to the GHR provides recent evidence-based recommendations and detailed guidance for clinicians providing pediatric preventive care.

Notes

Editor’s key points

  • ▸ The Greig Health Record (GHR) is an evidence-based care guide used in preventive care visits for children and adolescents aged 6 to 17 years old.

  • ▸ In this third update, the following topics are new or revised: confidentiality, capacity, and consent; developmental assessment; poverty screening; sexual health and consent; menstrual health history; contraception; guidance for detection and prevention of sexually transmitted infections; radon as an environmental hazard; updated ferritin standards; vaccine hesitancy; and updated dosing for human papillomavirus vaccination.

Points de repère du rédacteur

  • ▸ Le Relevé médical Greig (RMG) est un guide sur les soins de santé préventifs fondés sur des données probantes à utiliser lors des rendez-vous avec des enfants et des adolescents de 6 à 17 ans.

  • ▸ Dans cette troisième actualisation, les sujets suivants sont nouveaux ou révisés : la confidentialité, la capacité et le consentement; l’évaluation développementale; le dépistage de la pauvreté; Ia santé sexuelle et le consentement; les antécédents en santé menstruelle; la contraception; des conseils sur la détection et la prévention des infections transmises sexuellement; le radon en tant que danger environnemental; les normes actualisées pour la ferritine; l’hésitation vaccinale; et le dosage actualisé pour la vaccination contre le virus de papillome humain.

Footnotes

  • Contributors

    All authors contributed to conducting the literature review and to preparing the manuscript for submission.

  • Competing interests

    None declared

  • This article has been peer reviewed.

References

  1. 1.↵
    1. Greig A,
    2. Constantin E,
    3. Carsley S,
    4. Cummings C.
    Preventive health care visits for children and adolescents aged six to 17 years: The Greig Health Record - Executive Summary. Paediatr Child Health. 2010 Mar;15(3):157-62. doi: 10.1093/pch/15.3.157.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Canadian Paediatric Society
    . Greig Health Record [Internet]. Canadian Paediatric Society; 2016 [cited 2025 Oct 27]. Available from: http://www.cps.ca/tools-outils/greig-health-record.
  3. 3.↵
    1. Greig AA,
    2. Constantin E,
    3. LeBlanc CM,
    4. Riverin B.
    An update to the Greig Health Record: Executive summary. Paediatr Child Health. 2016 Jun-Jul;21(5):265-72. doi: 10.1093/pch/21.5.265.
    OpenUrlCrossRef
  4. 4.↵
    1. Dibden L,
    2. Kaufman M.
    Confidentiality for adolescents in the patient/physician relationship. Paediatr Child Health. 1997 Jan;2(1):19-20. doi: 10.1093/pch/2.1.19.
    OpenUrlCrossRef
  5. 5.
    1. Klein JD,
    2. Matos Auerbach M.
    Improving adolescent health outcomes. Minerva Pediatr. 2002 Feb;54(1):25-39.
    OpenUrlPubMed
  6. 6.↵
    1. Agostino H,
    2. Toulany A.
    Considerations for privacy and confidentiality in adolescent health care service delivery. Paediatr Child Health. 2023 May 16;28(3):172-83. doi: 10.1093/pch/pxac117.
    OpenUrlCrossRef
  7. 7.↵
    1. Morton WJ,
    2. Westwood M.
    Informed consent in children and adolescents. Paediatr Child Health. 1997 Sep;2(5):329-33. doi: 10.1093/pch/2.5.329.
    OpenUrlCrossRef
  8. 8.↵
    1. Canadian Medical Protective Association
    . Consent: A guide for Canadian Physicians [Internet]. Canadian Medical Protective Association; 2023 Aug [cited 2025 Oct 27]. Available from: https://www.cmpa-acpm.ca/en/advice-publications/handbooks/consent-a-guide-for-canadian-physicians.
  9. 9.↵
    1. Canadian Paediatric Society; Bioethics Committee
    . Treatment decisions regarding infants, children and adolescents. Paediatr Child Health. 2004 Feb;9(2):99-114. doi: 10.1093/pch/9.2.99.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Etchells E,
    2. Sharpe G,
    3. Elliott C,
    4. Singer PA.
    Bioethics for clinicians: 3. Capacity. CMAJ. 1996 Sep 15;155(6):657-61.
    OpenUrlAbstract
  11. 11.↵
    1. Coughlin KW.
    Medical decision-making in paediatrics: Infancy to adolescence. Paediatr Child Health. 2018 May;23(2):138-146. doi: 10.1093/pch/pxx127. Epub 2018 Apr 12.
    OpenUrlCrossRef
  12. 12.↵
    1. Dosman C,
    2. Sahagian Whalen S,
    3. Koscielnuk D, et al
    . Crucial skills in child development—school Age. Developmental attainments chart [Internet]. PedsCases; 2025. Available from: https://www.pedscases.com/crucial-skills-school-age-developmental-attainments-chart-1.
  13. 13.↵
    1. Campaign 2000
    . Ending child poverty: the time is now [Internet]. Campaign 2000; 2024 Nov 18 [cited 2025 Oct 27]. Available from: https://campaign2000.ca/ending-child-poverty-the-time-is-now.
  14. 14.↵
    1. Gupta RP,
    2. de Wit ML,
    3. McKeown D.
    The impact of poverty on the current and future health status of children. Paediatr Child Health. 2007 Oct;12(8):667-72. doi: 10.1093/pch/12.8.667.
    OpenUrlCrossRefPubMed
  15. 15.
    1. American Psychological Association
    . Mental health effects of poverty, hunger, and homelessness on children and teens. American Psychological Association; 2024 May [cited 2025 Oct 27]. Available from: http://www.apa.org/pi/families/poverty.aspx.
  16. 16.
    1. Reiss F.
    Socioeconomic inequalities and mental health problems in children and adolescents: a systematic review. Soc Sci Med. 2013 Aug;90:24-31. doi: 10.1016/j.socscimed.2013.04.026. Epub 2013 May 4.
    OpenUrlCrossRefPubMed
  17. 17.
    1. Men F,
    2. Elgar FJ,
    3. Tarasuk V.
    Food insecurity is associated with mental health problems among Canadian youth. J Epidemiol Community Health. 2021 Aug;75(8):741-8. doi: 10.1136/jech-2020-216149. Epub 2021 Feb 12.
    OpenUrlAbstract/FREE Full Text
  18. 18.
    1. Paquin V,
    2. Muckle G,
    3. Bolanis D,
    4. Courtemanche Y, et al
    . Longitudinal Trajectories of Food Insecurity in Childhood and Their Associations With Mental Health and Functioning in Adolescence. JAMA Netw Open. 2021 Dec 1;4(12):e2140085. doi: 10.1001/jamanetworkopen.2021.40085.
    OpenUrlCrossRef
  19. 19.↵
    1. Anderson KK,
    2. Clemens KK,
    3. Le B,
    4. Zhang L, et al
    . Household food insecurity and health service use for mental and substance use disorders among children and adolescents in Ontario, Canada. CMAJ. 2023 Jul 24;195(28):E948-55. doi: 10.1503/cmaj.230332.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Centre for Effective Practice
    . Poverty [Internet]. Centre for Effective Practice; 2016 Nov [cited 2025 Oct 27]. Available from: https://cep.health/clinical-products/poverty-a-clinical-tool-for-primary-care-providers/.
  21. 21.↵
    1. Persaud N,
    2. Sabir A,
    3. Woods H,
    4. Sayani A, et al
    . Preventive care recommendations to promote health equity. CMAJ. 2023 Sep 25;195(37):E1250-E1273. doi: 10.1503/cmaj.230237. Erratum in: CMAJ. 2023 Nov 14;195(44):E1520. doi: 10.1503/cmaj.231447.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Reno H,
    2. Park I,
    3. Workowski K,
    4. Machefsky A, et al
    . Guide to Taking a Sexual History [Internet]. Centers for Disease Control and Prevention; 2022 [cited 2025 Oct 27]. Available from: https://www.cdc.gov/sti/hcp/clinical-guidance/taking-a-sexual-history.html?CDC_AAref_Val=https://www.cdc.gov/std/treatment/SexualHistory.htm.
  23. 23.↵
    1. Johnson N.
    Comprehensive sexual health assessments for adolescents. Paediatr Child Health. 2020 Dec 16;25(8):551-2. doi: 10.1093/pch/pxaa122.
    OpenUrlCrossRef
  24. 24.↵
    1. Public Health Agency of Canada
    . Sexually Transmitted and Blood Borne Infections (STBBI) prevention guide [Internet]. Government of Canada; 2025 Jan 20 [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/stbbi-prevention-guide.html.
  25. 25.↵
    1. Department of Justice Canada
    . Age of Consent to Sexual Activity [Internet]. Government of Canada; 2023 Nov 21 [cited 2025 Oct 27]. Available from: https://www.justice.gc.ca/eng/rp-pr/other-autre/clp/faq.html.
  26. 26.↵
    1. Houston AM,
    2. Abraham A,
    3. Huang Z,
    4. D’Angelo LJ.
    Knowledge, attitudes, and consequences of menstrual health in urban adolescent females. J Pediatr Adolesc Gynecol. 2006 Aug;19(4):271-5. doi: 10.1016/j.jpag.2006.05.002.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Matteson KA,
    2. Zaluski KM.
    Menstrual Health as a Part of Preventive Health Care. Obstet Gynecol Clin North Am. 2019 Sep;46(3):441-53. doi: 10.1016/j.ogc.2019.04.004.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Deligeoroglou E,
    2. Tsimaris P,
    3. Deliveliotou A,
    4. Christopoulos P, et al
    . Menstrual disorders during adolescence. Pediatr Endocrinol Rev. 2006 Jan;3 Suppl 1:150-9.
    OpenUrlPubMed
  29. 29.↵
    1. Harel Z.
    Dysmenorrhea in adolescents and young adults: etiology and management. J Pediatr Adolesc Gynecol. 2006 Dec;19(6):363-71. doi: 10.1016/j.jpag.2006.09.001.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Peacock A,
    2. Alvi NS,
    3. Mushtaq T.
    Period problems: disorders of menstruation in adolescents. Arch Dis Child. 2012 Jun;97(6):554-60. doi: 10.1136/adc.2009.160853. Epub 2010 Jun 24.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Centers for Disease Control and Prevention
    . About Heavy Menstrual Bleeding [Internet]. Centers for Disease Control and Prevention; 2024 May 15 [cited 2025 Oct 27]. Available from: https://www.cdc.gov/female-blood-disorders/about/heavy-menstrual-bleeding.html.
  32. 32.↵
    1. US Preventive Services Task Force
    . Screening for iron deficiency anemia, including iron supplementation for children and pregnant women: recommendation statement. Am Fam Physician. 2006;74:461-6.
    OpenUrl
  33. 33.↵
    1. Graham RA,
    2. Davis JA,
    3. Corrales-Medina FF.
    The Adolescent with Menorrhagia: Diagnostic Approach to a Suspected Bleeding Disorder. Pediatr Rev. 2018 Dec;39(12):588-600. doi: 10.1542/pir.2017-0105.
    OpenUrlFREE Full Text
  34. 34.↵
    1. Di Meglio G,
    2. Crowther C,
    3. Simms J.
    Contraceptive care for Canadian youth. Paediatr Child Health. 2018 Jul;23(4):271-7. doi: 10.1093/pch/pxx192. Epub 2018 Jun 12.
    OpenUrlCrossRef
  35. 35.↵
    1. Black A,
    2. Guilbert E; Co-Authors;
    3. Costescu D, et al
    . Canadian Contraception Consensus (Part 1 of 4). J Obstet Gynaecol Can. 2015 Oct;37(10):936-42. doi: 10.1016/s1701-2163(16)30033-0.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Black A,
    2. Guilbert E; Co-Authors;
    3. Costescu D, et al
    . Canadian Contraception Consensus (Part 2 of 4). J Obstet Gynaecol Can. 2015 Nov;37(11):1033-9. doi: 10.1016/s1701-2163(16)30054-8.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Society of Obstetricians and Gynaecologists of Canada
    . Chapter 3 Emergency Contraception. J Obstet Gynaecol Can. 2015 Oct;37(10 Suppl):S20-8. doi: 10.1016/S1701-2163(16)39372-0.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Mierzejewska A,
    2. Walędziak M,
    3. Merks P,
    4. Różańska-Walędziak A.
    Emergency contraception - A narrative review of literature. Eur J Obstet Gynecol Reprod Biol. 2024 Aug;299:188-92. doi: 10.1016/j.ejogrb.2024.06.015. Epub 2024 Jun 13.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Bancsi A,
    2. Grindrod K.
    Update on medical abortion. Can Fam Physician. 2020 Jan;66(1):42-4.
    OpenUrlFREE Full Text
  40. 40.↵
    1. Society of Obstetricians and Gynaecologists of Canada
    . Emergency Contraception [Internet]. The Society of Obstetricians and Gynaecologists of Canada; 2017 [cited 2025 Oct 27]. Available from: https://www.sexandu.ca/contraception/emergency-contraception/.
  41. 41.↵
    1. Korownyk C,
    2. Kraut RY,
    3. Kolber MR.
    Vaginal self-swabs for chlamydia and gonorrhea. Can Fam Physician. 2018 Jun;64(6):448.
    OpenUrlFREE Full Text
  42. 42.↵
    1. US Preventive Services Task Force;
    2. Davidson KW,
    3. Barry MJ,
    4. Mangione CM, et al
    . Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Sep 14;326(10):949-56. doi: 10.1001/jama.2021.14081.
    OpenUrlCrossRefPubMed
  43. 43.
    1. Marcus JL,
    2. Bernstein KT,
    3. Kohn RP,
    4. Liska S, et al
    . Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis. 2011 Oct;38(10):922-4. doi: 10.1097/OLQ.0b013e31822a2b2e.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Centers for Disease Control and Prevention
    . Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep. 2014 Mar 14;63(RR-02):1-19.
    OpenUrlPubMed
  45. 45.↵
    1. Van Ommen CE,
    2. Malleson S,
    3. Grennan T.
    A practical approach to the diagnosis and management of chlamydia and gonorrhea. CMAJ. 2023 Jun 19;195(24):E844-9. doi: 10.1503/cmaj.221849.
    OpenUrlFREE Full Text
  46. 46.↵
    1. Government of Canada
    . Mpox: For health professionals [Internet]. Government of Canada; 2025 Oct 10 [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/diseases/mpox/health-professionals.html.
  47. 47.↵
    1. Public Health Agency of Canada
    . Interim guidance on the use of Imvamune® in the context of a routine immunization program [Internet]. Government of Canada; 2024 May 24 [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-interim-guidance-imvamune-routine-immunization-program.htm.
  48. 48.↵
    1. Tan DHS,
    2. Hull MW,
    3. Yoong D,
    4. Tremblay C, et al
    . Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017 Nov 27;189(47):E1448-58. doi: 10.1503/cmaj.170494. Erratum in: CMAJ. 2018 Jun 25;190(25):E782. doi: 10.1503/cmaj.180718.
    OpenUrlFREE Full Text
  49. 49.
    1. Hempel A,
    2. Biondi MJ,
    3. Baril JG,
    4. Tan DHS.
    Pre-exposure prophylaxis for HIV: effective and underused. CMAJ. 2022 Sep 6;194(34):E1164-70. doi: 10.1503/cmaj.220645.
    OpenUrlFREE Full Text
  50. 50.
    1. Trischuk T,
    2. Little B,
    3. LeBras M.
    Providing HIV preexposure prophylaxis. Can Fam Physician. 2022 Mar;68(3):197-201. doi: 10.46747/cfp.6803197.
    OpenUrlFREE Full Text
  51. 51.
    1. US Preventive Services Task Force
    . Final Recommendation Statement: Prevention of Acquisition of HIV: Preexposure Prophylaxis [Internet]. US Preventive Services Task Force; 2023 Aug 22 [cited 2025 Oct 27]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis.
  52. 52.
    1. Public Health Agency of Canada
    . Approach to HIV Screening [Internet]. Government of Canada; 2020 Dec [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-factsheet-types-screening-tests.html.
  53. 53.↵
    1. Public Health Agency of Canada
    . HIV and AIDS: for Health Professionals [Internet]. Government of Canada; 2025 Jan 14 [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/diseases/hiv-aids/health-professionals.html.
  54. 54.↵
    1. Tan DHS,
    2. Hull MW,
    3. Yoong D,
    4. Tremblay C, et al
    . Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017 Nov 27;189(47):E1448-58. doi: 10.1503/cmaj.170494. Erratum in: CMAJ. 2018 Jun 25;190(25):E782. doi: 10.1503/cmaj.180718.
    OpenUrlFREE Full Text
  55. 55.↵
    1. Billick MJ,
    2. Sheps J,
    3. Bogoch II.
    Post-exposure prophylaxis-in-pocket for HIV prevention. Can Fam Physician. 2024 Feb;70(2):107-8. doi: 10.46747/cfp.7002107.
    OpenUrlFREE Full Text
  56. 56.↵
    1. Health Canada
    . Cross-Canada Survey of Radon Concentrations in Homes - Final Report [Internet]. Government of Canada; 2012 Mar [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/radiation/cross-canada-survey-radon-concentrations-homes-final-report-health-canada-2012.html.
  57. 57.↵
    1. Statistics Canada
    . Environment Fact Sheets: Radon awareness in Canada [Internet]. Government of Canada; 2016 Dec 16 [cited 2025 Oct 27]. Available from: https://www150.statcan.gc.ca/n1/pub/16-508-x/16-508-x2016002-eng.htm.
  58. 58.↵
    1. Health Canada
    . Radon - Reduction Guide for Canadians [Internet]. Government of Canada; 2023 Feb [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/radiation/radon-reduction-guide-canadians-health-canada.html.
  59. 59.↵
    1. Naveed K,
    2. Goldberg N,
    3. Shore E,
    4. Dhoot A, et al
    . Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi study. Int J Lab Hematol. 2023 Jun;45(3):377-86. doi: 10.1111/ijlh.14016. Epub 2023 Jan 5.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Shen SC,
    2. Dubey V.
    Addressing vaccine hesitancy: Clinical guidance for primary care physicians working with parents. Can Fam Physician. 2019 Mar;65(3):175-81.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. MacDonald NE,
    2. Desai S,
    3. Gerstein B.
    Working with vaccine-hesitant parents: An update. Paediatr Child Health. 2018 Dec;23(8):561-2. doi: 10.1093/pch/pxy144. Epub 2018 Nov 19.
    OpenUrlCrossRef
  62. 62.↵
    1. Salvadori MI.
    Human papillomavirus vaccine for children and adolescents. Paediatr Child Health. 2018 Jul;23(4):262-5. doi: 10.1093/pch/pxx179. Epub 2018 Jun 12.
    OpenUrlCrossRef
  63. 63.↵
    1. Public Health Agency of Canada
    . Human papillomavirus (HPV) vaccines: Canadian Immunization Guide [Internet]. Government of Canada; 2024 Aug 1 [cited 2025 Oct 27]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Respond to this article
2025 update of the Greig Health Record
Anita Greig, Fereshte Lalani, Cara Dosman, Akshay Verma, Jordana Sheps, Naima Javaid
Canadian Family Physician Jan 2026, 72 (1) 31-38; DOI: 10.46747/cfp.720131
Twitter logo Facebook logo Mendeley logo

Jump to section

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.

More in this TOC Section

Similar Articles